2022
An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma
Madoff DC, Abi-Jaoudeh N, Braxton D, Goyal L, Jain D, Odisio BC, Salem R, Schattner M, Sheth R, Li D. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma. The Oncologist 2022, 27: 884-891. PMID: 35925597, PMCID: PMC9526481, DOI: 10.1093/oncolo/oyac139.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaBiomarker testingMultidisciplinary teamImage-guided liver biopsyMetastatic intrahepatic cholangiocarcinomaEvidence-based guidelinesIntrahepatic biliary treeNext-generation sequencingActionable genetic alterationsTreatment landscapeLiver biopsyMedical oncologistsInterventional oncologistsPoor prognosisAggressive malignancyBiliary treeTissue acquisitionBiopsy methodImaging modalitiesDesmoplastic natureGenetic alterationsTissue collectionNeedle choicePrecision medicineCholangiocarcinoma
2021
Management of Refractory Ascites Due to Portal Hypertension: Current Status.
Madoff DC, Cornman-Homonoff J, Fortune BE, Gaba RC, Lipnik AJ, Yarmohammadi H, Ray CE. Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 2021, 298: 493-504. PMID: 33497318, DOI: 10.1148/radiol.2021201960.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRefractory ascitesPortal hypertensionTransjugular intrahepatic portosystemic shuntLarge-volume paracentesesCirrhotic portal hypertensionAvailable therapeutic optionsIntrahepatic portosystemic shuntStepwise management approachMost patientsMedical managementPoor prognosisPortosystemic shuntTherapeutic optionsTreatment optionsMultiple therapiesPatient outcomesAppropriate treatmentClinical experienceDrainage deviceSpecific patientAscitesHypertensionPatientsParacentesesPrognosis